Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. (OTLK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
otlk · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Outlook Therapeutics, Inc. (OTLK) measures how much investors pay for each dollar of the company's trailing earnings. OTLK's current PE ratio of N/A is calculated by dividing its stock price of $0.72 by its TTM earnings per share of -$0.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Outlook Therapeutics, Inc.You OTLK | $30M | N/A | — | -$0.74 |
 Coeptis Therapeutics, Inc. COEP | $58M | N/A | — | -$2.81 |
 Cue Biopharma, Inc. CUE | $79M | N/A | — | -$8.42 |
 Equillium, Inc. EQ | $104M | N/A | — | -$0.24 |
 Werewolf Therapeutics, Inc. HOWL | $18M | N/A | — | -$1.32 |
 IO Biotech, Inc. IOBT | $1M | N/A | — | -$1.45 |
 Century Therapeutics, Inc. IPSC | $189M | N/A | — | -$0.11 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-1.79 | — | |
2024-09-30 FY2024 | — | $-4.06 | — | |
2023-09-30 FY2023 | — | $-4.72 | — | |
2022-09-30 FY2022 | — | $-6.23 | — | |
2021-09-30 FY2021 | — | $-6.96 | — | |
2020-09-30 FY2020 | — | $-9.71 | — | |
2019-09-30 FY2019 | — | $-37.96 | — | |
2018-09-30 FY2018 | — | $-195.40 | — | |
2017-09-30 FY2017 | — | $-258.75 | — | |
2016-09-30 FY2016 | — | $-592.24 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Outlook Therapeutics, Inc. (OTLK) measures how much investors pay for each dollar of the company's trailing earnings. OTLK's current PE ratio of N/A is calculated by dividing its stock price of $0.72 by its TTM earnings per share of -$0.74.
Frequently asked questions
OTLK pe ratio · 6 questionsOTLK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.72 and TTM EPS of -$0.74. Data sourced from Financial Modeling Prep via OTLK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Outlook Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09